Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$2.62 +3.1%	$2.10	$0.77 ▼ $4.08	$351.24M	1.41	954,826 shs	522,551 shs
ITOS iTeos Therapeutics	$10.09 -0.2%	$8.48	$4.80 ▼ $18.13	$386.95M	1.51	678,330 shs	740,101 shs
KOD Kodiak Sciences	$3.61 -0.6%	$3.78	$1.92 ▼ $11.60	$191.53M	2.27	349,108 shs	236,065 shs
LGST Semper Paratus Acquisition	$4.51	$4.52	$4.08 ▼ $12.03	$71.35M	-0.08	30,930 shs	12,596 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	+3.15%	+19.63%	+25.36%	+28.43%	+136.04%
ITOS iTeos Therapeutics	-0.20%	+0.70%	+17.87%	+55.23%	-32.24%
KOD Kodiak Sciences	-0.55%	+1.69%	+4.94%	+19.93%	+32.23%
LGST Semper Paratus Acquisition	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMPX Compass Therapeutics	2.962 of 5 stars	4.6	1.0	0.0	0.0	0.0	5.0	0.0
ITOS iTeos Therapeutics	3.3735 of 5 stars	4.1	4.0	0.0	0.0	0.6	3.3	0.6
KOD Kodiak Sciences	4.3484 of 5 stars	3.0	4.0	0.0	4.6	3.0	3.3	0.0
LGST Semper Paratus Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPX Compass Therapeutics	3.11	Buy	$13.13	400.95% Upside
ITOS iTeos Therapeutics	2.14	Hold	$15.86	57.16% Upside
KOD Kodiak Sciences	2.00	Hold	$9.00	149.31% Upside
LGST Semper Paratus Acquisition	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest LGST, ITOS, KOD, and CMPX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$13.00 ➝ $12.00
5/28/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $12.00
5/14/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $13.00
5/14/2025	ITOS iTeos Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
5/14/2025	ITOS iTeos Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $12.00
5/14/2025	ITOS iTeos Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/14/2025	ITOS iTeos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/14/2025	ITOS iTeos Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$47.00 ➝ $9.00
5/13/2025	ITOS iTeos Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$15.00 ➝ $8.00
5/9/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
4/29/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$17.00 ➝ $16.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPX Compass Therapeutics	$850K	426.23	N/A	N/A	$0.91 per share	2.88
ITOS iTeos Therapeutics	$35M	11.03	N/A	N/A	$16.16 per share	0.62
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.86 per share	N/A
LGST Semper Paratus Acquisition	N/A	N/A	$0.33 per share	13.74	($1.10) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPX Compass Therapeutics	-$49.38M	-$0.41	N/A	N/A	N/A	N/A	-42.47%	-38.31%	8/11/2025 (Estimated)
ITOS iTeos Therapeutics	-$134.41M	-$3.04	N/A	N/A	N/A	N/A	-21.37%	-18.55%	8/6/2025 (Estimated)
KOD Kodiak Sciences	-$176.21M	-$3.63	N/A	N/A	N/A	N/A	-115.71%	-54.17%	8/13/2025 (Estimated)
LGST Semper Paratus Acquisition	$4.41M	N/A	0.00	∞	N/A	N/A	-21.83%	3.10%	N/A

Latest LGST, ITOS, KOD, and CMPX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	KOD Kodiak Sciences	-$0.89	-$1.09	-$0.20	-$1.09	N/A	N/A
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
4/28/2025	Q1 2025	ITOS iTeos Therapeutics	-$0.94	-$0.80	+$0.14	-$0.80	$9.35 million	N/A
3/27/2025	Q4 2024	KOD Kodiak Sciences	-$0.90	-$0.84	+$0.06	-$0.84	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
LGST Semper Paratus Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPX Compass Therapeutics	N/A	8.33	8.33
ITOS iTeos Therapeutics	N/A	14.13	14.13
KOD Kodiak Sciences	N/A	4.62	4.62
LGST Semper Paratus Acquisition	N/A	0.22	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPX Compass Therapeutics	68.43%
ITOS iTeos Therapeutics	97.16%
KOD Kodiak Sciences	89.06%
LGST Semper Paratus Acquisition	N/A

Insider Ownership

Company	Insider Ownership
CMPX Compass Therapeutics	29.80%
ITOS iTeos Therapeutics	12.50%
KOD Kodiak Sciences	45.90%
LGST Semper Paratus Acquisition	56.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
ITOS iTeos Therapeutics	90	38.27 million	33.49 million	Optionable
KOD Kodiak Sciences	90	52.76 million	28.55 million	Optionable
LGST Semper Paratus Acquisition	2,021	15.82 million	6.86 million	Not Optionable

LGST, ITOS, KOD, and CMPX Headlines

Recent News About These Companies

LGST.3850 Immigration Law (Formerly 41.385)

April 26, 2024 | uml.edu

LGST.3760 Family Law (Formerly 41.376)

March 27, 2024 | uml.edu

Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGN

February 14, 2024 | finance.yahoo.com

Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGN

February 14, 2024 | globenewswire.com

SPAC Semper Paratus shareholders okay merger with Tevogen Bio

February 1, 2024 | msn.com

Semper Paratus Acquisition Corporation’s Shareholders Approve Business Combination with Tevogen Bio

February 1, 2024 | finance.yahoo.com

Semper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on Nasdaq

January 24, 2024 | finance.yahoo.com

Semper Paratus Acquisition Corp (LGST)

January 10, 2024 | investing.com

Tevogen Bio Inc. and Semper Paratus Acquisition Corporation Announce Effectiveness of Registration Statement for Business Combination

January 5, 2024 | finance.yahoo.com

With a 56% stake, Semper Paratus Acquisition Corporation (NASDAQ:LGST) insiders have a lot riding on the company

December 5, 2023 | finance.yahoo.com

Semper Paratus Acquisition Corporation Regains Compliance with Certain Nasdaq Listing Requirement

September 29, 2023 | finance.yahoo.com

Semper Paratus Acquisition Corporation Files Registration Statement on Form S-4 in Connection with Proposed Business Combination with Tevogen Bio Inc

September 14, 2023 | finance.yahoo.com

Tevogen to go public via merger with SPAC Semper Paratus

June 30, 2023 | msn.com

Biotech firm Tevogen Bio enters $1.2 bln SPAC deal for US listing

June 29, 2023 | reuters.com

Semper Paratus Acquisition Corp Class A

June 27, 2023 | morningstar.com

Semper Paratus Acquisition Corporation (LGST)

April 17, 2023 | finance.yahoo.com

Semper Paratus Acq Stock (NASDAQ:LGSTU), Trade Ideas

February 24, 2023 | benzinga.com

Semper Paratus Acquisition Corp. Cl A

January 25, 2023 | wsj.com

Saba Capital Management, L.P. Buys FTAC Zeus Acquisition Corp, Semper Paratus Acquisition Corp, ...

February 18, 2022 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGST, ITOS, KOD, and CMPX Company Descriptions

Compass Therapeutics NASDAQ:CMPX

$2.62 +0.08 (+3.15%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$2.60 -0.02 (-0.73%)

As of 04:02 AM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

iTeos Therapeutics NASDAQ:ITOS

$10.09 -0.02 (-0.20%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$10.10 +0.01 (+0.05%)

As of 06/24/2025 04:38 PM Eastern

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Kodiak Sciences NASDAQ:KOD

$3.61 -0.02 (-0.55%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$3.82 +0.22 (+5.96%)

As of 06/24/2025 05:44 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Semper Paratus Acquisition NASDAQ:LGST

Semper Paratus Acquisition Corporation does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company intends to acquire companies operating in the transportation, supply chain, and logistics industries. Semper Paratus Acquisition Corporation was incorporated in 2021 and is based in New York, New York. Semper Paratus Acquisition Corporation operates as a subsidiary of Ssvk Associates, Llc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time